THE EFFECT OF DPP4 INHIBITOR ON RENAL ANEMIA IN HEMODIALYSIS PATIENTS

被引：0
作者：
Aono, Masaki [1 ]
Sato, Yuzuru [1 ]
机构：
[1] Sato Junkanki Hosp, Internal Med, Matsuyama, Ehime, Japan
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2015年 / 30卷
关键词：
D O I：
10.1093/ndt/gfv182.4
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
FP656
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The Change of Adenosine Deaminase (ADA) Activity in Patients with Type 2 Diabetes and the Effect of DPP4 Inhibitor Treatment on ADA Activity
    Lee, Jae-Geun
    Koh, Gwanpyo
    Kim, Youngree
    Lee, Daeho
    DIABETES, 2010, 59 : A196 - A197
  • [22] The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
    Zhang, Tianli
    Tong, Xiang
    Zhang, Shijie
    Wang, Dongguang
    Wang, Lian
    Wang, Qian
    Fan, Hong
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [23] Effect of Darbepoetin Alfa on Renal Anemia in Japanese Hemodialysis Patients
    Kusaba, Tetsuro
    Ishida, Ryo
    Nakayama, Mayuka
    Kato, Hisato
    Uchiyama, Hitoji
    Sato, Katsuaki
    Mori, Yasukiyo
    Matsubara, Hiroaki
    Kajita, Yoshihiro
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2009, 59 (09): : 435 - 439
  • [24] Impact of DPP4 inhibitor saxagliptin on body weight of patients with type 2 diabetes: a clinical observation
    Zhang, Rui
    Zheng, Hongting
    Xu, Qiang Tong Jing
    Wang, Hui
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2016, 32 (SUPP 2) : 40 - 41
  • [25] A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects
    Bloomfield, Daniel M.
    Krishna, Rajesh
    Hreniuk, David
    Hickey, Lisa
    Ghosh, Kalyan
    Bergman, Arthur J.
    Miller, Jutta
    Gutierrez, Maria J.
    Stoltz, Randall
    Gottesdiener, Keith M.
    Herman, Gary A.
    Wagner, John A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (08) : 937 - 946
  • [26] The effect of kidney transplantation therapy on renal anemia in hemodialysis patients
    不详
    BLOOD PURIFICATION, 2004, 22 (04) : 391 - 392
  • [27] DPP4 in Cardiometabolic Disease Recent Insights From the Laboratory and Clinical Trials of DPP4 Inhibition
    Zhong, Jixin
    Maiseyeu, Andrei
    Davis, Stephen N.
    Rajagopalan, Sanjay
    CIRCULATION RESEARCH, 2015, 116 (08) : 1491 - 1504
  • [28] Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes
    Na, Yewon
    Kim, Soo Wan
    Park, Ie Byung
    Choi, Soo Jung
    Nam, Seungyoon
    Jung, Jaehun
    Lee, Dae Ho
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (11) : 3022 - 3034
  • [29] KRP-104, a uniquely prandial-targeted DPP4 inhibitor
    Plotkin, D. J.
    Lewin, A.
    Logan, D.
    Kato, T.
    Kozarich, J.
    Wei, X.
    Vest, J.
    Orloff, D.
    DIABETOLOGIA, 2012, 55 : S339 - S339
  • [30] Effects of the DPP4 inhibitor vildagliptin on post-MI cardiac remodeling
    Yin, M.
    Ruifrok, W. T.
    Qian, C.
    Sillje, H. H. W.
    Van Gilst, W. H.
    De Boer, R. A.
    EUROPEAN HEART JOURNAL, 2010, 31 : 572 - 572
12345